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INTRODUCTION
Matrix metalloproteinases (MMP) are members of an
enzyme family the extent of whose involvement in
physiological and pathological situations is just
beginning to be appreciated. A case in point is the
vast array of normal and exacerbated immunological
responses involving T cell recruitment to a particular
site in the organism through the extracellular matrix
(ECM). In order to penetrate and migrate through the
ECM, T cells need to lyse their way through a variety
of connective tissue proteins. We review herein the
available evidence for a role of MMPs secreted by T
cells to allow them to migrate. We will then examine
the data indicating that MMPs are not solely secreted
by migrating T cells but that adjacent stromal cells
also do their part, Finally, we will review a number of
instances where MMP dysregulation is associated
with some important T-cell dependent pathologies.
EXPRESSION OFMMP BY T CELLS WILL
DICTATE THEIR CAPACITY TO MIGRATE
THROUGH EXTRACELLULAR MATRIX
MMPs are zinc-dependent enzymes and include col-
lagenases, gelatinases A and B, the stromelysins,
matrylisins, metalloelastase, and the membrane-type
metalloproteinases (Massova et al., 1998). Most of
the members of the MMP family are secreted by cells
into the extracellular space; nonetheless, some mem-
brane-type MMPs (MT-MMP) attached to the cell
surface have also been described (Sato et al., 1994,
Strongin et al., 1995, Matsumoto et al., 1997, Shofuda
et al., 1997, Pei, 1999), and shown, like their secreted
counterparts, to participate in the enzymatic cascade
that leads to the degradation of proteins of the ECM.
Circulating T cells in a resting state express a very
limited repertoire of MMPs. Constitutive expression
of only MT1-MMP, MMP-2, and MMP-9 have been
reported to be expressed in resting T cells (Weeks et
al., 1993, Leppert et al., 1995, Graesser et al., 1998).
It is the recruitment of T cells to the inflamed
endothelium via secretion of chemokines that initiates
a cascade of activation events leading to both the
expansion of the MMP repertoire by T cells, as well
and the increase of the expression level of specific
MMPs. Chemokines that are released locally during
an inflammatory response, such as RANTES, VIE
and MIP, are likely the first modulators that initiate
the expansion of the MMP repertoire in T cells, judg-
ing from their ability to induce in vitro the expression
of MMP-9 in T cells (Xia et al., 1996). Although
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binding of L-selectin on the surface of neutrophils can
also induce neutrophils to secrete MMP-9 (Wize et
al., 1998), there is as yet no indication that the reper-
toire ofMMPs can be modulated during the rolling of
T lymphocytes on the inflamed endothelium. In con-
trast, firm contact between circulating T cells and the
endothelial cells via cell adhesion molecules is impor-
tant for the induction of MMP genes in T cells; we
have shown that upregulation of MMP-9 required
direct contact with endothelial cells, since antibodies
to LFA-1 and ICAM-1 blocked such an upregulation
(Aoudjit et al., 1998). In this particular case, the bind-
ing to ICAM-1 was essential but not sufficient to
induce MMP-9 in T lymphoma cells. In other models,
however, signaling via integrins alone was sufficient
to induce MMP genes, as VCAM-l-induced the
expression ofMMP-1 in T cells (Leppert et al., 1995).
Romanic et al. (1994) have also demonstrated that
MMP-2 was induced in T cells by adhesion to
endothelial cells through the binding of T cell VLA-4
to VCAM-1. It is hypothesized that the induction of
MMP-2 by autoreactive T-cell clones via VLA-4 is
necessary for the clones to induce experimental
autoimmune encephalomyelitis (EAE), a mouse
model for human multiple sclerosis (Graesser et al.,
1998). Thus, the sequence of the initial events is as
follows: 1) inflammatory cytokines produced at the
extracellular inflammatory site reachs the vascular
endothelium, 2) the endothelium becomes
"inflamed", induces and expresses CAMs, such as
ICAM-1 and VCAM-1, 3) circulating T cells via
integrins adhere to the inflamed endothelium, 4) acti-
vation ofMMP genes occurs in T cells, and 5) secre-
tion ofMMPs confers to T cells an invasive behavior,
allowing them to migrate across the vascular wall and
deep in the tissue. This is consistent with the idea that
memory T cells, which express high levels of VLA-4
and/or LFA-1 on their surface, have an increased
capacity to cross the basal lamina and penetrate the
tissue stroma. The intracellular signaling pathways
that lead to MMP expression in T cells have only
been partially characterized, but possibly involve
PKC-mediated signaling pathways, as PKC activators
have been shown to induce in T cells the expression
of MMP-9, MMP-10, and MMP-13 (Weeks et al.,
1993, Zhou et al., 1993, Conca and Wilmroth, 1994,
Aoudjit et al., 1997, Wilmroth et al., 1998). The
development of a repertoire of MMPs by T cells is
therefore a dynamic process that is initiated during
the first steps of the cascade of adhesion molecule
interactions.
T CELL-DEPENDENT INDUCTION OF MMP
IN STROMAL CELLS
The source of MMPs at inflammatory sites is not,
however, restricted to the secretion by infiltrating
cells: indeed stromal cells themselves can secrete
MMPs on contact with infiltrating cells. This idea has
emerged from an increasing number of studies in
tumor models. Although MMP secretion was initially
associated with metastatic cells, in situ hybridization
has shown that normal cells surrounding the tumors
can also secrete MMPs. Histological examination of
tumor-containing tissues in patients with squamous
cell carcinomas and malignant epithelium have
shown that MMP mRNA was expressed not only by
tumor cells, but also by normal peritumoral cells as
well (Pyke et al., 1992, Basset et al., 1997). In some
cases, the expression of MMP-9 was exclusively
found in the stroma surrounding the tumors (Karelina
et al., 1993). In was indeed shown that contact with
several types of tumor cells in vitro induced expres-
sion ofMMP-9 in fibroblasts (Himelstein et al., 1994,
Miyagi et al., 1995, Aoudjit et al., 1997), and a new
member of the MMP family, stromelysin-3, was iden-
tified specifically in stromal cells surrounding inva-
sive breast carcinomas (Basset et al., 1990).
Fibroblasts surrounding human breast carcinoma cells
have also been implicated in invasion and/or metasta-
sis through the production of MT-MMP, which is
thought to facilitate, via activation of MMP-2, the
transition of human breast carcinoma cells from a
fibroblast- like phenotype to an epithelial-mesenchy-
mal tumorigenic state (Gilles et al., 1997). The impor-
tance ofMMP production by stromal cells was further
emphasized by the same group who showed, using a
co-implantation assay, that fibroblasts of strome-
lysin-3-deficien mice had lost the capacity to pro-T CELL CONTROL OF EX TRARCELLULAR MATRIX 173
mote implantation of MCF-7 human malignant
epithelial cells in nude mice (Masson et al., 1998).
Although the mechanism by which MMPs enhance
tumor growth is yet unclear, there are several indica-
tions that such overexpression of MMP could act by
stimulating angiogenesis. The recent report by Werb’s
group in which MMP-9-deficient mice exhibited an
abnormal pattern of skeletal growth plate vasculariza-
tion and ossification due to defective angiogenesis,
strongly argues in favor of this possibility (Vu et al.,
1998).
There is increasing evidence that such an induction
ofMMP secretion by stromal cells can also be opera-
tive when circulating T cells migrate to an inflamma-
tory site, most notably when they first encounter the
vascular endothelium. In this context, our group has
shown that T lymphoma cells could induce MMP-9
expression in endothelial cells by TNF (mem-
brane-bound or soluble) (Aoudjit et al., 1998). This
cytokine can also induce other members of the MMP
family, such as MT1-MMP (Rajavashisth et al.,
1999), while other cytokines, such as TGFI]I, can
upregulate MMP-2 and MMP-9 in endothelial cells
(Puyraimond et al., 1999). Adhesion molecules on T
cells, most notably the CD40 ligand, can also promote
the expression of MMPs in endothelial cells, thereby
contributing to the vascular remodeling and the neo-
formation of vessels during atherogenesis and other
chronic immune reactions (Mach et al., 1999). The
capacity ofT cells to induce the secretion ofMMPs in
stromal cells via CD40/CD40L continues even after
the cells have crossed the vascular cell wall and pene-
trated the tissue stroma; this is shown by the fact that
they can induce the expression of MMP-1, MMP-2,
MMP-3, and MMP-9 in vascular smooth muscle cells
(Schonbeck et al., 1997), thereby supporting the
development or maintenance of chronic inflammatory
lesions. Isolated membranes from T cell lines
expressing high levels of the CD40 ligand also stimu-
late the expression of mRNA and the production of
MMP-9 by human monocytic cells (Malik N et al.,
1996). Upregulation ofMMP gene expression in stro-
mal cells is, however, cell-type specific: contact of T
cells via the CD40/CD40L pathway with gingival
fibroblasts inhibits their constitutive or induced pro-
duction of MMP-1 and MMP-3 (Wassenaar A et al.,
1999), a mechanism thought to delay further perio-
dontal tissue damage during chronic periodontitis.
These results establish the CD40/CD40L as an impor-
tant pathway regulating the induction of MMPs in
stromal cells upon contact with T cells.
THE DELICATE BALANCE BETWEENMMP
AND THEIR NATURAL INHIBITORS
The balance between matrix formation and destruc-
tion is maintained by the presence of naturally occur-
ring tissue inhibitors of metalloproteinases (TIMPs).
Four members of the TIMP family, designated as
TIMP-1 to -4, have been identified to date (Denhardt
et al., 1993, Greene et al., 1993, Apte et al., 1994,
Leco et al., 1994, Silbiger et al., 1994, Leco et al.,
1997). TIMPs have a molecular weight of approxi-
mately 25-30 kDa and bind to both latent and active
MMPs through strong interactions with the hemo-
pexin- like domain of the enzyme, forming a stable
and catalytically inert, 1:1 stoichiometric
enzyme-inhibitor complex that inhibits activation of
the proenzyme in physiologic conditions
(Gomis-Ruth et al., 1997).
T lymphocytes are among the cells that have been
shown to secrete a restricted repertoire of TIMP
genes; TIMP-2 is often expressed constitutively,
whereas TIMP-1 is inducible by activation with vari-
ous stimuli, such as PKC activators. To date, there is
no evidence that, in T cells, TIMP-3 or TIMP-4 are
expressed constitutively, or upon activation.
TIMP-4-specific transcripts are expressed abun-
dantly in the heart, moderately in tissues such as kid-
neys, colon, testis, ovary, and skeletal muscles, and
not at all in the thymus and the spleen (Greene et al.,
1996, Leco et al., 1997). Abundant transcripts encod-
ing TIMP-3 were also detected in kidneys, lungs, and
brain, but not in lymphoid tissues. In contrast to
TIMP-2 and TIMP-4, however, TIMP-3, like
TIMP-1, is encoded by an inducible gene, most nota-
bly upon exposure to T cell-dependent factors, as its
expression is stimulated by AP-1 and NF-kB activa-
tors, by 12-O-tetradecanoylphorbol- 13-acetate, and174 YVES ST-PIERRE and EDOUARD E POTWOROWSKI
by TNF (Sun et al, 1995). The consequences of T
cell-induced modulation ofTIMP secretion often vary
according to the T cell factor implicated arid the target
cells; no systematic study, however, has been done
and only anecdotal data are available. For instance,
whereas TIMP-1 is upregulated in monocytes, syn-
oviocytes, uterine cervical fibroblasts, endothelial
cells, and lung fibroblasts upon exposure to IL-1 or
IL-6, the same TIMP-1 is downregulated when bron-
chial epithelial cells are treated with TNFo (Yao et
al., 1997). Decreased TIMP-3 secretion in synovial
lining cells has also been reported upon exposure to
Oncostatin M (Gatsios et al., 1996). The decrease in
TIMP expression or the increase in MMP production
will thus necessarily tip the balance in favor of
enhanced metalloproteinase activity, leading to ECM
turnover, and tissue remodeling.
Like other proteins, TIMP:MMP complexes
formed in the extracellular space are sensitive to pro-
teolysis by extracellular proteases; moreover, in some
cases, partial proteolysis of the complex can free
TIMP from the complex, release active MMP, and
shift the balance toward ECM proteolysis. One of the
most potent enzymes for carrying out this task is the
neutrophil elastase (NE), a protease which is abun-
dantly secreted following massive neutrophil infiltra-
tion. NE can degrade into small fragments the
inhibitory TIMP-1 molecule (Okada et al., 1988),
even if it is bound to MMP-9, thereby freeing MMP-9
and shifting the balance toward ECM proteolysis
(Itoh et al., 1995). NE is not normally expressed in T
cells, although elastolytic activity has been reported
to be associated with the T cell receptor complex in
some T cell lines (Bristow and Flood, 1993) and
malignant T cell lymphomas (Kossakowska et al.,
1998). To further complicate matter, NE can indi-
rectly induce MMP secretion by T cells and stromal
cells since fragmentation of ECM proteins, such as
laminin, exposes TNFo binding sites on these frag-
ments. This not only serves to restrict TNFo to sites
adjacent to the inflammation, but possibly induce
MMP secretion via binding of CD4-positive T cells to
these templates (Hershkoviz et al., 1995). Given the
fact that NE further participates in the connective tis-
sue destruction at inflammatory sites by its direct
action on elastin and other ECM proteins, NE must be
considered as a key participant in the tissue remode-
ling by MMPs at inflammatory sites.
DYSREGULATION OFMMP SECRETION IN T
CELL-MEDIATED INFLAMMATORY
PROCESSES
It is no surprise that MMP secretion is, in most cases,
transient and highly regulated, since abnormal secre-
tion of MMPs may be highly detrimental, most nota-
bly by favoring angiogenesis and tumor metastasis.
The capacity of cancer cells to invade the stroma is
attributed to their ability to secrete MMPs capable of
degrading the extracellular matrix of basement mem-
branes (reviewed by Powell and Matrisian, 1997). To
date, the best in vivo evidence for the implication of
MMPs in neoplasia comes from gene transfer experi-
ments using experimental models of metastasis in
which tumor cells were transfected with vectors
encoding TIMP or MMP genes, or inhibitory anti-
sense sequences. Whereas transfection ofTIMP genes
or ofMMP antisense into tumor cells inhibited tumor
growth (Hua and Muschel, 1996; Wang et al., 1997;
Seghal et al., 1998, Valente et al., 1998), expression
ofMMPs in non-metastatic cells by gene transfection
rendered them capable of disseminating and forming
tumors at distant sites (Powell et al., 1993; Bernhardt
et al., 1994; Tsunezuka et al., 1996). The expression
of TIMPs in transgenic mice has also been shown to
exert a suppressive effect on metastasizing tumor,
most notably in the case of brain fibrosarcoma
(Kruger A, et al., 1998), and lymphoma (Kruger et al.,
1997).
There is increasing evidence that an imbalance
between MMPs and the associated TIMPs can play a
decisive role in several degenerative diseases with an
autoimmune etiology, such as rheumatoid arthritis,
and multiple sclerosis (MS). MS is characterized by
massive release of extracellular proteases. The most
common forms of proteases released in extracellular
environment include NE, cathepsins, and MMPs.
Immunohistochemical studies of the MS brain tissue
suggested that monocytes, macrophages and reactiveT CELL CONTROL OF EX TRARCELLULAR MATRIX 175
astrocytes are potential sources of increased Cathep-
sin B levels in MS brain (Bever and Garver, 1995).
The most common protease associated with MS, how-
ever, is MMP-9 (Gijbels et al., 1993). Analysis of cer-
ebrospinal fluids samples from 52 patients with
relapsing-remitting and primary progressive MS
showed abnormally high levels ofMMP-9 (Leppert et
al., 1998). This increase was found even in clinically
stable patients, suggesting that progressive tissue
damage results from an ongoing proteolysis by
MMP-9. A priori, the role played by proteases in
chronic inflammation and autoimmunity consists of
cleaving ECM proteins, such as collagen, thereby dis-
rupting the blood brain barrier and facilitating the
infiltration of effector cells, most notably T cells,
monocytes, PMN, and NK cells. In the case of MS,
the ability of proteases to degrade myelin basic pro-
tein (MBP) may be crucial (Gijbels et al., 1993). Not
only does the degradation of the myelin sheath dam-
age neuronal functions of the CNS, it also generates
proteolytic fragments that contribute to local
auto-immune reaction against MBP antigens. The
positions of the cleavage sites in human MBP follow-
ing degradation by MMP-9 is such that at least one
peptide coincides with a documented major
MBP-autoantigen (Proost et al., 1993). Other MMPs,
such as matrilysin (MMP-7) can also degrade MBP;
indeed an injection of MMP-7 and MMP-9 into the
brain parenchyma induces loss of myelin integrity
(Anthony et al., 1998). Cathepsins are also capable of
degrading MBR thereby contributing to the release of
potential MBP auto-antigens (Cao et al., 1999). The
efficacy of IFN[ treatment in MS patients may be in
part due to the ability of this drug to decrease MMP-9
activity, leading to a reduction of T-lymphocyte infil-
tration into the CNS (Leppert et al., 1996, Stuve et al.,
1996).
Selective inhibition of MMPs could be a useful
approach to counter the progression of autoimmune
degenerative disorders where extensive tissue remod-
eling is present. There is an increasing number of
ongoing clinical trials focusing on the potential bene-
fit ofMMP inhibitors (Parsons SL, et al. 1997, Beattie
GJ, et al. 1998, Bramhall SR, 1998, Wojtowicz-Praga
Set al., 1998, Brown PD, 1999, Primrose JN et al.,
1999). These trials have so far been restricted mostly
to the field of cancer, where MMPs have been shown
to favor angiogenesis and confer invasive behavior to
metastatic cells (Bernhard et al., 1994). However,
with a better understanding of the role of MMPs in
the immune response and disorders, it is likely that
MMP inhibitors will be used in the treatment of
chronic autoimmune disorders where ongoing prote-
olysis and degenerative tissue remodeling occur.
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